We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Efficacy of Everolimus in Patients with Metastatic Insulinomas and Refractory Hypoglycemia: For the French Group of Endocrine Tumors (GTE-Renaten).
- Authors
Bernard, V.; Lombard-Bohas, C.; Goichot, B.; Rohmer, V.; Guimbaud, R.; Niccoli, P.; Chougnet, C.; Ruszniewski, P.; Baudin, E.
- Abstract
Introduction: Refractory hypoglycemia in patients with metastatic insulinomas (RHMI) is an important cause of morbidity and mortality and Everolimus could be a new therapeutic option. Aim(s): To evaluate the time to first symptomatic recurrence (TSR) after Everolimus initiation in patients with RHMI. Materials and methods: Patients with RHMI and treated with Everolimus between 2007 and 2011 were analysed in a restrospective multicentric study within the French group of endocrine tumors. Ongoing hyperglycemic medical options and safety were recorded. Results: Twelve patients were included; Everolimus was given after a median of four previous therapeutic lines and median duration was 6.5 months (range, 1.5-32+= ongoing months). Clinical benefits were observed in 11 patients. Median TSR was 6.5 months (range, 0-32+): seven and five patients remained symptom free for more than three and six months, respectively. Five patients were still treated at 6, 7, 10, 12 and 32+ months. Six patients discontinued additional hyperglycemic therapies, including three glucose infusions. Three patients discontinued Everolimus because of pulmonary side effects at 1.5, 3 and 7 months of initiation: Two deaths occurred (one non-infectious pneumonitis and one pneumocistis pneumonia). Three patients discontinued Everolimus because of disease progression at 2, 3 and 10 months of initiation, without hypoglycemia recurrence. Conclusion: Everolimus appears to be a new effective treatment modality for RHMI. Pulmonary tolerance should be carefully monitored.
- Subjects
INSULINOMA; HYPOGLYCEMIA; CANCER treatment; CANCER invasiveness; ENDOCRINE diseases; PANCREATIC diseases
- Publication
Neuroendocrinology, 2012, Vol 96, p20
- ISSN
0028-3835
- Publication type
Article